Novel Hormone Replacer Holds Up Long-Term for Hypoparathyroidism
SEATTLE -- Nearly all patients with chronic hypoparathyroidism were able to remain off conventional therapy with active…
Browsing Tag
Hypoparathyroidism
MBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone…
CARMEL, Ind., Oct. 05, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an…
Amolyt Pharma to Host Hybrid Key Opinion Leader Event on its Potential…
LYON, France and CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specializing in the development of therapeutic peptides for rare endocrine and…
Amolyt Pharma Announces Two Presentations, Including Phase 2a Data for AZP-3601 in…
LYON, France and CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related…
MBX Biosciences Receives Orphan Drug Designation for Lead Candidate MBX 2109 for the…
CARMEL, Ind., July 26, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing precision endocrine peptide therapeutics to treat endocrine…
HypoPARAthyroidism Association Launches the First-of-its-Kind Patient-Powered Data…
Hypoparathyroidism affects an estimated 100,000 people in the United States, and there are currently no widely available FDA-approved treatment options to address the underlying disease…
FreeStyle Libre 3 OK’d; P2 Win for Hypoparathyroidism Tx; Saxenda a…
The FDA cleared the next-generation FreeStyle Libre 3 system, a 14-day continuous glucose monitor…
Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with…
– For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control (p-value <0.0001). – TransCon PTH demonstrated statistically…
Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH…
–– 58 of the original 59 subjects continue in the open-label extension portion of the Phase 2 trial. –– Phase 3 data for TransCon PTH expected in Q1 2022. COPENHAGEN, Denmark, Nov. 18,…
Ascendis Pharma A/S Announces Target Enrollment Achieved in the Phase 3 PaTHway Trial…
– Ascendis expects to complete enrollment of subjects still in screening within one week – – PaTHway top-line data now anticipated in Q1 2022 and submission of a New Drug Application…